DUBLIN--(BUSINESS WIRE)-- Prothena Corporation plc (PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, ...
DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation ...
DUBLIN--(BUSINESS WIRE)-- Prothena Corporation plc (PRTA) today announced that the Company has initiated an approximate 63% reduction in its workforce to substantially reduce its operating costs to ...
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results